Literature DB >> 8770884

Both the 5' and 3' noncoding regions of the thyrotropin receptor messenger ribonucleic acid influence the level of receptor protein expression in transfected mamalian cells.

A Kakinuma1, G Chazenbalk, S Filetti, S M McLachlan, B Rapoport.   

Abstract

The molecular basis for the difference in the bioresponsiveness of TSH receptor cell lines from two different laboratories has been investigated. We modified our 4-kb TSH receptor complementary DNA (cDNA) by deleting either the 5' untranslated region (UTR), the 3'UTR, or both UTRs. The 5'UTR contains two false AUG initiation codons followed by a stop codon. The cDNAs in the eukaryotic expression vector pSV2-NEO-ECE, as well as the 5'3'UTR-truncated cDNA in pSVL, were stably transfected into Chinese hamster ovary cells. Pools of more than 100 colonies were studied in order to minimize insertion site-dependent variation in the level of expression. Scatchard analysis of TSH binding indicated that the number of receptors on the surface of Chinese hamster ovary cells expressing the wild-type transcript (approximately 16,000/cell) increased approximately 2-fold with 5'UTR deletion, approximately 5-fold with 3'UTR deletion, and approximately 10-fold with both 5'UTR and 3'UTR deletion. TSH binding affinities of all constructs were in the range of 2-5 x 10(-10) M. No significant difference was evident between the 5'3'UTR truncated cDNAs in the two different vectors, pSV2-NEO-ECE and pSVL. The increase in the amplitude of the cAMP response to TSH stimulation was commensurate with the number of receptors expressed on the surface of the different cell lines. Truncation of the 5'UTR did not alter TSH receptor messenger RNA (mRNA) levels relative to the wild-type mRNA. In contrast, the level of the 3'UTR-truncated transcript, as well as the 5'3'UTR-deleted transcript, increased approximately 4-fold independent of the expression vector used. In summary, both the 5'UTR and 3'UTR of the human TSH receptor mRNA influence the level of receptor expression on transfected mammalian cells. In particular, the 3'UTR has a destabilizing influence on the MRNA. These data explain the greater level of TSH receptor expression in cell lines that are transfected with cDNA lacking these regions of the mRNA transcript.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770884     DOI: 10.1210/endo.137.7.8770884

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  The DREAM protein is associated with thyroid enlargement and nodular development.

Authors:  Marcos Rivas; Britt Mellström; Begoña Torres; Gaetano Cali; Alfonso M Ferrara; Daniela Terracciano; Mariastella Zannini; Gabriella Morreale de Escobar; Jose R Naranjo
Journal:  Mol Endocrinol       Date:  2009-03-19

3.  Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies.

Authors:  Alexander V Misharin; Yuji Nagayama; Holly A Aliesky; Yumiko Mizutori; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

4.  Vitamin D deficiency modulates Graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization.

Authors:  Alexander Misharin; Martin Hewison; Chun-Rong Chen; Venu Lagishetty; Holly A Aliesky; Yumiko Mizutori; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2008-10-16       Impact factor: 4.736

5.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.